Equillium, Inc. (EQ)Healthcare | Biotechnology | La Jolla, United States | NasdaqCM
2.05 USD
+0.07
(3.535%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.92 -0.13 (-0.127%) ⇩ (April 17, 2026, 6:03 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:38 p.m. EDT
Equillium (EQ) presents a binary opportunity driven by $50M financing news, evidenced by the massive disconnect between call and put volume. While fundamentals remain negative due to net losses and unprofitability, the zero dividend and strong 'strong buy' consensus, paired with technical proximity to the 50-day average, create a high-conviction short-term momentum play (~4 stars). The options flow confirms traders are positioning for a breakout above $2.50 within the coming month. Long-term potential depends entirely on clinical trial success, warranting a hold/buy for thesis investors (3 stars) but making this a tactical buy for momentum traders. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.398797 |
| AutoARIMA | 0.419229 |
| AutoETS | 0.419783 |
| AutoTheta | 0.420000 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 5.73 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.068 |
| Excess Kurtosis | 0.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.514 |
| Market Cap | 129,614,440 |
| Forward P/E | -8.20 |
| Beta | 1.74 |
| Website | https://www.equilliumbio.com |
As of April 18, 2026, 10:38 p.m. EDT: Options market shows a pronounced bullish skew. Call volume significantly exceeds put volume (approx. 30:1), indicating strong speculative positioning for upside. The 2026-07-17 strike at 2.5 is the dominant anchor for calls across expirations, suggesting speculators view this level as the immediate resistance target. Put interest is negligible and clustered at the money (2.5) with low volume, failing to create a protective floor. Implied volatility is relatively suppressed for deep OTM calls (1.3-1.6 vs 9.11 at far OTM strikes), suggesting the market expects movement but narratives are priced in near-term volatility while premium is sought for longer-dated growth plays.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.4565215 |
| Address1 | 2,223 Avenida De La Playa |
| Address2 | Suite 105 |
| All Time High | 27.05 |
| All Time Low | 0.27 |
| Ask | 2.07 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 380,700 |
| Average Daily Volume3 Month | 495,622 |
| Average Volume | 495,622 |
| Average Volume10Days | 380,700 |
| Beta | 1.743 |
| Bid | 2.02 |
| Bid Size | 1 |
| Book Value | 0.465 |
| City | La Jolla |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.05 |
| Current Ratio | 10.579 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.07 |
| Day Low | 1.92 |
| Debt To Equity | 2.514 |
| Display Name | Equillium |
| Earnings Timestamp End | 1,754,942,400 |
| Earnings Timestamp Start | 1,754,510,400 |
| Ebitda | -23,518,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.254 |
| Enterprise Value | 100,056,440 |
| Eps Current Year | -0.21667 |
| Eps Forward | -0.25 |
| Eps Trailing Twelve Months | -0.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.8796 |
| Fifty Day Average Change | 0.1703999 |
| Fifty Day Average Change Percent | 0.09065753 |
| Fifty Two Week Change Percent | 345.65216 |
| Fifty Two Week High | 2.7 |
| Fifty Two Week High Change | -0.6500001 |
| Fifty Two Week High Change Percent | -0.24074078 |
| Fifty Two Week Low | 0.27 |
| Fifty Two Week Low Change | 1.78 |
| Fifty Two Week Low Change Percent | 6.5925922 |
| Fifty Two Week Range | 0.27 - 2.7 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,539,351,000,000 |
| Float Shares | 31,498,206 |
| Forward Eps | -0.25 |
| Forward P E | -8.2 |
| Free Cashflow | -14,327,250 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.20111999 |
| Held Percent Institutions | 0.60890996 |
| Implied Shares Outstanding | 63,226,556 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. |
| Long Name | Equillium, Inc. |
| Market | us_market |
| Market Cap | 129,614,440 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_575585027 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -22,398,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 128,982,174 |
| Number Of Analyst Opinions | 7 |
| Open | 2.06 |
| Operating Cashflow | -22,746,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 240 1200 |
| Post Market Change | -0.12669992 |
| Post Market Change Percent | -6.1804843 |
| Post Market Price | 1.9233 |
| Post Market Time | 1,776,463,421 |
| Previous Close | 1.98 |
| Price Eps Current Year | -9.461392 |
| Price Hint | 4 |
| Price To Book | 4.408602 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.356 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | 0.0699999 |
| Regular Market Change Percent | 3.53535 |
| Regular Market Day High | 2.07 |
| Regular Market Day Low | 1.92 |
| Regular Market Day Range | 1.92 - 2.07 |
| Regular Market Open | 2.06 |
| Regular Market Previous Close | 1.98 |
| Regular Market Price | 2.05 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 155,340 |
| Return On Assets | -0.51386 |
| Return On Equity | -0.93995005 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 63,226,556 |
| Shares Percent Shares Out | 0.0431 |
| Shares Short | 2,727,834 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,082,323 |
| Short Name | Equillium, Inc. |
| Short Percent Of Float | 0.0546 |
| Short Ratio | 4.42 |
| Source Interval | 15 |
| State | CA |
| Symbol | EQ |
| Target High Price | 12.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 6.28571 |
| Target Median Price | 6.0 |
| Total Cash | 30,277,000 |
| Total Cash Per Share | 0.479 |
| Total Debt | 719,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.3442 |
| Two Hundred Day Average Change | 0.70579994 |
| Two Hundred Day Average Change Percent | 0.5250706 |
| Type Disp | Equity |
| Volume | 155,340 |
| Website | https://www.equilliumbio.com |
| Zip | 92,037 |